Last reviewed · How we verify
Intravenous Sedation
Intravenous sedation depresses the central nervous system to induce a state of reduced consciousness and anxiety relief for medical procedures.
Intravenous sedation depresses the central nervous system to induce a state of reduced consciousness and anxiety relief for medical procedures. Used for Procedural sedation for diagnostic and therapeutic medical procedures, Anxiolysis and sedation during surgery or invasive interventions.
At a glance
| Generic name | Intravenous Sedation |
|---|---|
| Sponsor | Moscow Regional Research and Clinical Institute (MONIKI) |
| Drug class | Sedative/Hypnotic (class varies by specific agent used) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Procedural Sedation |
| Phase | FDA-approved |
Mechanism of action
IV sedation works by administering sedative agents (commonly benzodiazepines, propofol, or opioids) directly into the bloodstream, which rapidly cross the blood-brain barrier and bind to GABAergic or other CNS receptors to suppress neural activity. This produces anxiolysis, amnesia, and varying degrees of unconsciousness depending on the agent and dose, allowing patients to undergo diagnostic or therapeutic procedures with reduced awareness and discomfort.
Approved indications
- Procedural sedation for diagnostic and therapeutic medical procedures
- Anxiolysis and sedation during surgery or invasive interventions
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Nausea and vomiting
- Oversedation
- Allergic reactions
Key clinical trials
- Can Nitrous Oxide (Laughing Gas) be Used as a Sedative for GI Endoscopy Procedures? (PHASE4)
- Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2) (PHASE3)
- Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1) (PHASE3)
- Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Investigator-initiated, International, Multicentre, Superiority, Randomized, Open-label, Clinical Trial. (PHASE4)
- TEAS for Sedation During ERCP: A Multicenter Trial (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Optimal Insertion Time During Remimazolam-Remifentanil Anesthesia for Painless Gastroscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Sedation CI brief — competitive landscape report
- Intravenous Sedation updates RSS · CI watch RSS
- Moscow Regional Research and Clinical Institute (MONIKI) portfolio CI